Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4296065 Target Snapshot

Cyclin-dependent kinase 1/ G1/S-specific cyclin-D3 · PROTEIN COMPLEX · Homo sapiens

43Compounds
2Assays
1Approved Drugs
59.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P06493. Use UniProt P06493 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P06493 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cyclin-dependent kinase 1/ G1/S-specific cyclin-D3 as ChEMBL target CHEMBL4296065, mapped to UniProt P06493. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cyclin-dependent kinase 1/ G1/S-specific cyclin-D3
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4296065
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P06493
Cyclin-dependent kinase 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cyclin-dependent kinase 1/ G1/S-specific cyclin-D3 is the right protein anchor across sources, using UniProt P06493 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCyclin-dependent kinase 1
UniProt AccessionP06493
Component TypeProtein
Sequence Length297 aa

Cyclin-dependent kinase 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Cyclin-dependent kinase 1/ G1/S-specific cyclin-D3, mapped to UniProt P06493. ChEMBL maps the protein component as Cyclin-dependent kinase 1. Sequence length is 297 aa.

Mapped IDP06493
Review nameCyclin-dependent kinase 1/ G1/S-specific cyclin-D3
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase II
Assay Mix

Activity Type Distribution

IC5059.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4289226 9.62 IC50 0.24 Preclinical
CHEMBL4277525 9.38 IC50 0.42 Preclinical
CHEMBL4279832 9.37 IC50 0.43 Preclinical
CHEMBL4287693 9.3 IC50 0.5 Preclinical
CHEMBL4287743 9.02 IC50 0.96 Preclinical
CHEMBL4281514 9.0 IC50 1.0 Preclinical
CHEMBL4294940 8.96 IC50 1.09 Preclinical
CHEMBL4284301 8.76 IC50 1.74 Preclinical
CHEMBL4285830 8.59 IC50 2.56 Preclinical
CHEMBL4286100 8.55 IC50 2.83 Preclinical
Distribution

pChEMBL Value Distribution

3
5.0
17
5.5
3
6.0
2
6.5
6
7.0
6
7.5
8
8.0
6
8.5
7
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

ABEMACICLIB
CHEMBL3301610
Approved 2017
Assay Landscape

Assay Landscape

2
Total Assays
24
Tested Compounds
2
Assay Types
ADME — 1 assays, 24 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 24 5.8
Binding — 1 assays, 20 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 1 20 8.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine